Program
Prednisolone
Also written as “Desloratadine + Prednisolone”, “prednisolone” and “Desloratadine , Prednisolone”.
Its studies are mostly in Prostatic Neoplasms · Arthritis, Rheumatoid · Rhinitis, Allergic · Asthma · Pulmonary Disease, Chronic Obstructive, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 50 open or running | phase 3since Mar 11, 2010 | Aug 24, 2005 | none ahead |
| Sanofi | 50 open or running | phase 4since Feb 26, 2014 | Jul 9, 2007 | none ahead |
| EMS | 40 open or running | phase 3since Sep 5, 2011 | Sep 5, 2011 | none ahead |
| Astellas Pharma | 32 open or running | phase 2since May 27, 2025 | Jun 26, 2024 | Oct 31, 2027phase 2 · NCT07052929 |
| adapt-produtos-oftalmolo-gicos-ltda | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Bausch Health Companies | 10 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Biogen | 10 open or running | phase 4since Jul 29, 2010 | Jul 29, 2010 | none ahead |
| Chong Kun Dang Pharmaceutical | 10 open or running | phase 4since Jan 3, 2019 | Jan 3, 2019 | none ahead |
| Eurofarma Laboratorios | 10 open or running | phase 3since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Hamad Medical | 10 open or running | phase 3since Nov 7, 2012 | Nov 7, 2012 | none ahead |
| Hoffmann-La Roche | 10 open or running | phase 2since Sep 6, 2013 | Sep 6, 2013 | none ahead |
| Ultragenyx Pharmaceutical | 10 open or running | phase 3since Jul 14, 2021 | Jul 14, 2021 | none ahead |
| zalicus | 10 open or running | phase 2since Jun 7, 2011 | Jun 7, 2011 | none ahead |
Also a collaborator on its studies: elan-pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Aug 24, 2005.
- Sep 5, 2011EMS's first study: phase 3 study in EczemaNew to EMSEMS · NCT01429701 · 76 enrolled
- Feb 6, 20122 phase 3 studiesEMS · NCT01529242, NCT01529229
- Oct 31, 2012Phase 3 study in Rhinitis, AllergicEMS · NCT01720485 · 234 enrolled · Brazil
- Nov 7, 2012Hamad Medical's first study: phase 3 study in Arthritis, RheumatoidNew to Hamad MedicalHamad Medical · NCT01724268 · 80 enrolled · Qatar
- Sep 6, 2013Hoffmann-La Roche's first study: phase 2 study in AsthmaNew to Hoffmann-La RocheHoffmann-La Roche · NCT01948401 · 54 enrolled · United Kingdom
- Feb 26, 2014Phase 4 study in Prostate Cancer MetastaticSanofi · NCT02074137 · 10 enrolled · India
- May 8, 2015Phase 4 study in Prostatic NeoplasmsSanofi · NCT02441894 · 21 enrolled · Japan
- Nov 2, 2017Phase 3 study in Multiple SclerosisSanofi · NCT03368664 · 16 enrolled · France, Italy, Poland and more
- Jan 3, 2019Chong Kun Dang Pharmaceutical's first study: phase 4 study in Kidney TransplantNew to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
- Jul 14, 2021Ultragenyx Pharmaceutical's first study: phase 3 study in Hepatorenal form of glycogen storage diseaseNew to Ultragenyx PharmaceuticalUltragenyx Pharmaceutical · NCT05139316 · 52 enrolled · United States, Brazil, Canada and more
- Dec 13, 2021Eurofarma Laboratorios's first study: phase 3 study in Rhinitis, AllergicNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT05214911 · 262 enrolled · Brazil
- Jun 26, 2024Astellas Pharma's first study: phase 1 study in Friedreich AtaxiaNew to Astellas PharmaAstellas Pharma · NCT06483802
- May 27, 2025Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT07005154 · 218 planned · United States, China, France and more
- Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929 · 9 planned · United States, Canada
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalAstellas Pharma · NCT07052929
- May 31, 2032Primary completion: phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT07005154
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Astellas Pharma | Oct 31, 2027 | 9 |
| NCT07005154Prostatic Neoplasms · United States, China, France and more | 2 | Recruiting | Astellas Pharma | May 31, 2032 | 218 |
| NCT06483802Friedreich Ataxia | 1 | Withdrawn | Astellas Pharma | Oct 22, 2025 | 0 |
| NCT05214911Rhinitis, Allergic · Brazil | 3 | Completed | Eurofarma Laboratorios | Mar 23, 2025 | 262 |
| NCT05139316Hepatorenal form of glycogen storage disease · United States, Brazil, Canada and more | 3 | Completed | Ultragenyx Pharmaceutical | Feb 20, 2024 | 52 |
| NCT03794492Kidney Transplant · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | Jul 22, 2022 | 169 |
| NCT03368664Multiple Sclerosis · France, Italy, Poland and more | 3 | Terminated | Sanofi | May 4, 2021 | 16 |
| NCT02441894Prostatic Neoplasms · Japan | 4 | Completed | Sanofi | Feb 2016 | 21 |
| NCT02074137Prostate Cancer Metastatic · India | 4 | Completed | Sanofi | Mar 2016 | 10 |
| NCT01948401Asthma · United Kingdom | 2 | Completed | Hoffmann-La Roche | Apr 2014 | 54 |
| NCT01724268Arthritis, Rheumatoid · Qatar | 3 | UNKNOWN | Hamad Medical | May 2014 | 80 |
| NCT01720485Rhinitis, Allergic · Brazil | 3 | UNKNOWN | EMS | Dec 2013 | 234 |
| NCT01529242Cutaneous Hypersensitivity · Brazil | 3 | Terminated | EMS | Aug 2016 | 17 |
| NCT01529229Rhinitis, Allergic | 3 | Completed | EMS | Oct 2014 | 210 |
| NCT01429701Eczema | 3 | Completed | EMS | Jun 2012 | 76 |
| NCT01369745Arthritis, Rheumatoid · United States | 2 | Completed | zalicus | Aug 2012 | 294 |
| NCT01603030Eye Infections · Brazil | 3 | UNKNOWN | adapt-produtos-oftalmolo-gicos-ltda | Aug 2012 | 66 |
| NCT01324583Prostatic Neoplasms · Japan | 1 | Completed | Sanofi | Nov 2014 | 48 |
| NCT01211665Immune Reconstitution Inflammatory Syndrome · United States, Germany | 4 | Terminated | Biogen | Feb 2012 | 3 |
| NCT01086410Asthma · United States, Germany, Poland | 3 | Completed | GlaxoSmithKline | Sep 2010 | 185 |
| NCT00498797Prostatic Neoplasms · Brazil, Germany, Hungary and more | 2 | Completed | Sanofi | Jul 2007 | 86 |
| NCT00384306Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | GlaxoSmithKline | Jan 2006 | 9 |
| NCT00379730Pulmonary Disease, Chronic Obstructive · Argentina, Chile, New Zealand and more | 1 | Completed | GlaxoSmithKline | 90 | |
| NCT00327197Asthma · United Kingdom | 1 | Terminated | GlaxoSmithKline | Jun 6, 2011 | 47 |
| NCT00198523Eye Infections · United States | 3 | Completed | Bausch Health Companies | Oct 2005 | 132 |
| NCT00134693Arthritis, Rheumatoid · Australia, France, Germany and more | 2 | Completed | GlaxoSmithKline | Aug 3, 2006 | 77 |
How it is read
Names in the registry
- “Prednisolone”, 17 entries
- “Desloratadine + Prednisolone”, 3 entries
- “prednisolone”, 3 entries
- “Desloratadine , Prednisolone”, 1 entry
- “Oral prednisolone”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 7 studies
- Arthritis, Rheumatoid, 4 studies
- Rhinitis, Allergic, 3 studies
- Asthma, 3 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.